Monoclonal antibodies in lymphoma: the first decade.

abstract：:Thrombus forms on catheters and other indwelling synthetic materials. Systemic heparin infusion decreases, but does not eliminate thrombus formation. The day is approaching when systemic heparinization may no longer be indicated to suppress catheter thrombogenesis. Passivation of catheters by heparin immobilization is...

journal_title：Seminars in hematology

authors： Eberhart RC,Clagett CP

更新日期：1991-10-01 00:00:00

abstract：:Both thalidomide and intermittent high-dose dexamethasone are agents with established activity against multiple myeloma. We summarized our experience with thalidomide alone, and then in combination with dexamethasone, for groups of patients with myeloma resistant or relapsing despite standard treatments. Criteria of r...

journal_title：Seminars in hematology

authors： Alexanian R,Weber D,Anagnostopoulos A,Delasalle K,Wang M,Rankin K

更新日期：2003-10-01 00:00:00

abstract：:Mouse models of transplantation have been indispensable to the development of bone marrow transplantation (BMT). Their role in the generation of basic science knowledge is invaluable and is subject to discussion below. However, this article focuses on the direct role and relevance of mouse models towards the clinical ...

journal_title：Seminars in hematology

authors： Arber C,Brenner MK,Reddy P

更新日期：2013-04-01 00:00:00

abstract：:For the majority of hematologic malignancies allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment option. Sibling donors have been the standard for adult patients. Since there is not a suitable family donor for all patients, the need for alternative donors for HCT is great. Fortunately, t...

journal_title：Seminars in hematology

authors： Sebastian Schäfer H,Finke J

更新日期：2016-04-01 00:00:00

abstract：:Imatinib mesylate (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ; Glivec, Novartis Pharma AG, Basel, Switzerland), a signal transduction inhibitor with preferential effects against the tyrosine kinase activity of the protein product of the ABL proto-oncogene, induced hematologic responses in >or=90% of pati...

journal_title：Seminars in hematology

authors： Hoelzer D,Gökbuget N,Ottmann OG

更新日期：2002-10-01 00:00:00

abstract：:Hodgkin Lymphoma (HL) is a lymphoproliferative disorder of B cells that commonly has a favorable prognosis when treated with either combination chemotherapy and radiation therapy, or chemotherapy alone. However, the prognosis for patients who relapse, or have evidence for refractory disease, is poor and new treatments...

journal_title：Seminars in hematology

authors： Younes A,Ansell SM

更新日期：2016-07-01 00:00:00

abstract：:Inhibition of antibody-coated platelet destruction in patients with immune thrombocytopenic purpura (ITP) is a well-known mechanism of treatment effect. A number of interventions that would ameliorate the thrombocytopenic effect of ITP patient plasma when infused into normal recipients were demonstrated in 1965. Subse...

journal_title：Seminars in hematology

authors： Bussel JB

更新日期：2000-07-01 00:00:00

abstract：:A new high-purity recombinant factor VIII preparation has been developed for the treatment of hemophilia A. Structurally, this factor VIII preparation, B-domain deleted recombinant factor VIII (BDDrFVIII), differs from other recombinant and plasma-derived factor VIII preparations in that most of the B-domain has been ...

journal_title：Seminars in hematology

authors： Sandberg H,Almstedt A,Brandt J,Castro VM,Gray E,Holmquist L,Lewin M,Oswaldsson U,Mikaelsson M,Jankowski MA,Bond M,Scoble HA

更新日期：2001-04-01 00:00:00

abstract：:Antibody-mediated rejection (AMR) is a major risk factor for graft loss following kidney transplantation. Traditional anti-humoral therapies provide suboptimal therapy and they do not deplete plasma cells, which are the source of antibody production. Proteasome inhibitors (PI) have been shown to deplete both transform...

journal_title：Seminars in hematology

authors： Sadaka B,Alloway RR,Shields AR,Schmidt NM,Woodle ES

更新日期：2012-07-01 00:00:00

abstract：:Untreated anemia is common in cancer patients. Previous studies have demonstrated that both the existence of cancer and treatment with chemotherapy can suppress the normal endogenous erythropoietic response to anemia, making some cancer patients transfusion cadidates. In placebo-controlled phase III studies, administr...

journal_title：Seminars in hematology

authors： Glaspy J

更新日期：1997-07-01 00:00:00

abstract：:Even though the overall outcome after allogeneic transplant has improved significantly in the last decades, late infectious diseases are still the most important causes of late morbidity and mortality. Here, impaired immune reconstitution and therapy of chronic graft-versus-host disease (GVHD) represent the major risk...

journal_title：Seminars in hematology

authors： Fuji S,Kapp M,Einsele H

更新日期：2012-01-01 00:00:00

abstract：:In this review, we discuss disease-causing alterations of RUNT-related transcription factor 1 (RUNX1), a master regulator of hematopoietic differentiation. Familial platelet disorder with predisposition to myeloid leukemia (FPDMM) typically presents with (1) mild to moderate thrombocytopenia with normal-sized platelet...

journal_title：Seminars in hematology

authors： Schlegelberger B,Heller PG

更新日期：2017-04-01 00:00:00

abstract：:The antiviral and antigrowth activity of interferon (IFN) makes this agent a promising approach to cancer therapy. Three tumors that are unusually sensitive to IFN-a are chronic myelogenous leukemia (CML) in the benign phase, hairy-cell leukemia, and the T-cell lymphomas associated with mycosis fungoides. Studies usin...

journal_title：Seminars in hematology

authors： Gutterman JU

更新日期：1988-07-01 00:00:00

abstract：:The presence or absence of minimal residual disease (MRD) in patients with multiple myeloma (MM) has emerged as a useful marker to determine the depth of remission. MRD negativity as an endpoint has been shown to be associated with improved progression-free survival in many studies. MRD detection is therefore part of ...

journal_title：Seminars in hematology

authors： Waldschmidt JM,Anand P,Knoechel B,Lohr JG

更新日期：2018-01-01 00:00:00

abstract：:Cytogenetic data suggest that acute myeloid leukemia (AML) develops through a process of branching evolution, especially during relapse and progression. Recent genomic data from AML cases using digital sequencing, temporal comparisons, xenograft cloning, and single-cell analysis indicate that most, if not all, AML cas...

journal_title：Seminars in hematology

authors： Welch JS

更新日期：2014-10-01 00:00:00

abstract：:Severe neutropenia renders patients susceptible to life-threatening bacterial and fungal infections. Despite improvements in supportive care and antimicrobial therapy, morbidity and mortality remains significant. Since the 1960s, granulocyte transfusions have been used to either treat or prevent serious infections in ...

journal_title：Seminars in hematology

authors： West KA,Conry-Cantilena C

更新日期：2019-10-01 00:00:00

abstract：:Thrombosis is a common and potentially serious complication of immune-mediated heparin-induced thrombocytopenia (HIT). Discontinuation of heparin is a simple and important maneuver in patients with suspected HIT. Unfortunately, thrombosis often occurs even in those patients in whom heparin was discontinued because of ...

journal_title：Seminars in hematology

authors： Warkentin TE

更新日期：1998-10-01 00:00:00

abstract：:Stem cell transplantation is a recognized treatment for many hematologic malignancies. Human leukocyte antigen (HLA) testing is a key assessment in the evaluation of potential recipients and selection of the appropriate stem cell donor. Over the past several years, technological advances have moved HLA testing from a ...

journal_title：Seminars in hematology

authors： Bray RA

更新日期：2001-04-01 00:00:00

abstract：:Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for most bone marrow (BM) failure syndromes and hemoglobinopathies. Over the past decade, umbilical cord blood (UCB) has been used more frequently as a stem cell source in patients who lack a suitable BM donor. Although graft failure ...

journal_title：Seminars in hematology

authors： MacMillan ML,Walters MC,Gluckman E

更新日期：2010-01-01 00:00:00

abstract：:From work particularly In the last two decades of the century, the cell populations forming blood cells can now be purified and cultured clonally so that blood cell formation can be analyzed in vitro. A large number of specific regulators of this process have been identified and mass-produced in recombinant form. Thre...

journal_title：Seminars in hematology

authors： Metcalf D

更新日期：1999-10-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenia and by increased progression to acute myelocytic leukemia (AML). With the exception of allogeneic stem cell transplantation, there is generally no curative treatment for these d...

journal_title：Seminars in hematology

authors： Fenaux P

更新日期：2004-04-01 00:00:00

abstract：:Analysis of data from 806 patients with newly diagnosed adult acute myelocytic leukemia (AML) (not including acute promyelocytic leukemia [APL] patients) treated at M.D. Anderson Cancer Center from 1995 through 1999 indicated that among patients entering a particular week of induction therapy, mortality rates were 6%,...

journal_title：Seminars in hematology

authors： Estey E

更新日期：2001-10-01 00:00:00

abstract：:Activation products of the terminal complement cascade potently affect granulocyte function, inducing, for example, their migration toward (chemotaxis), and adherence to (opsonization), microbes, and stimulating their production of microbicidal oxygen radicals such as superoxide anion, and the like. We present studies...

journal_title：Seminars in hematology

authors： Craddock PR,Hammerschmidt DE,Moldow CF,Yamada O,Jacob HS

更新日期：1979-04-01 00:00:00

abstract：:The risk of postoperative venous thromboembolism (VTE) is dependent on the type of surgical procedure and specific characteristics of the patient. Patients with intrinsic factors placing them at higher risk of VTE remain at high risk, even if the procedural risk is low. The identification of factors such as age, obesi...

journal_title：Seminars in hematology

authors： Samama MM

更新日期：2000-07-01 00:00:00

abstract：:5-Aza-2'-deoxycytidine (decitabine; Dacogen, MGI Pharma, Inc, Bloomington, MN) is a cytidine analog that inhibits DNA methyltransferases resulting in loss of DNA methylation with subsequent gene re-expression. This compound was first synthesized over 40 years ago and since that time much information has been learned r...

journal_title：Seminars in hematology

authors： Kantarjian HM,Issa JP

更新日期：2005-07-01 00:00:00

abstract：:The prolonged and severe myelosuppression associated with high-dose chemotherapy and autologous bone marrow transplantation is a major causative factor in patient morbidity and mortality resulting from infection and other causes. The recent molecular cloning, in vitro expression, and formulation of recombinant human c...

journal_title：Seminars in hematology

authors： Peters WP

更新日期：1989-04-01 00:00:00

abstract：:This phase I trial of idarubicin (IDA) was conducted in 32 patients with acute leukemia and chronic myelogenous leukemia (CML) in blastic crisis (CML/BC) who either had failed to achieve a complete remission (CR) after initial induction therapy or had relapsed after CR. IDA was administered at dosages ranging from an ...

journal_title：Seminars in hematology

authors： Tamura K

更新日期：1996-10-01 00:00:00

abstract：:Hydroxyurea (HU) is the first widely used treatment to have an impact on the severity of disease in adult patients with sickle cell anemia, but limited data are available for younger patients or those with variant genotypes. We reviewed 324 months of experience with HU in 16 patients from 5.3 to 18.4 years of age trea...

journal_title：Seminars in hematology

authors： Rogers ZR

更新日期：1997-07-01 00:00:00

abstract：:Advances in recombinant DNA manufacturing technology have now made possible the production of a highly purified and active recombinant factor IX (rFIX) product. Recombinant factor IX was developed by (1) stable insertion of the genes for both factor IX and PACE-SOL (a truncated, soluble serine protease needed to enhan...

journal_title：Seminars in hematology

authors： Harrison S,Adamson S,Bonam D,Brodeur S,Charlebois T,Clancy B,Costigan R,Drapeau D,Hamilton M,Hanley K,Kelley B,Knight A,Leonard M,McCarthy M,Oakes P,Sterl K,Switzer M,Walsh R,Foster W

更新日期：1998-04-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is probably the best understood human malignancy at the molecular level, but among the hardest to explain to patients concerning appropriate treatment options. At present, we do not know the long-term outcome of promising new therapies such as the tyrosine kinase inhibitor imatinib mesyl...

journal_title：Seminars in hematology

authors： Appelbaum FR

更新日期：2001-07-01 00:00:00